GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that researchers will present eight abstracts from its respiratory disease program at the Annual Meeting of the American Thoracic Society, from May 18 to 20, 2008 in Toronto, Canada. Presentations are designed to showcase MedImmune’s biologics capabilities.
“MedImmune is committed to finding innovative solutions that may one day help patients struggling with respiratory diseases,” said Tony Coyle, vice president, head, autoimmunity inflammation and respiratory disease research. “We are pleased to present a plethora of promising data that could potentially address diseases such as asthma and chronic obstructive pulmonary disease.”
The preceding presentations will occur on Tuesday, May 20 from 8:15 a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.
About MedImmune
MedImmune is wholly owned by AstraZeneca plc and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune’s website at www.medimmune.com.
CONTACT: Media: Sidoney Atse, +1-301-398-5990, or Investors: Peter Vozzo,
+1-301-398-4358, both of MedImmune
Web site: http://www.medimmune.com/
